- Home
- CISS vs JAGX Comparison
CISS vs JAGX Comparison
Compare CISS & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- JAGX
- Stock Information
- Founded
- CISS 2022
- JAGX 2013
- Country
- CISS Greece
- JAGX United States
- Employees
- CISS N/A
- JAGX N/A
- Industry
- CISS Marine Transportation
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- CISS Consumer Discretionary
- JAGX Health Care
- Exchange
- CISS Nasdaq
- JAGX Nasdaq
- Market Cap
- CISS 3.0M
- JAGX 3.1M
- IPO Year
- CISS N/A
- JAGX N/A
- Fundamental
- Price
- CISS $0.50
- JAGX $4.67
- Analyst Decision
- CISS
- JAGX
- Analyst Count
- CISS 0
- JAGX 0
- Target Price
- CISS N/A
- JAGX N/A
- AVG Volume (30 Days)
- CISS 57.1K
- JAGX 39.3K
- Earning Date
- CISS 05-27-2025
- JAGX 03-31-2025
- Dividend Yield
- CISS N/A
- JAGX N/A
- EPS Growth
- CISS N/A
- JAGX N/A
- EPS
- CISS N/A
- JAGX N/A
- Revenue
- CISS $42,296,101.00
- JAGX $11,689,000.00
- Revenue This Year
- CISS N/A
- JAGX $18.18
- Revenue Next Year
- CISS N/A
- JAGX $40.06
- P/E Ratio
- CISS N/A
- JAGX N/A
- Revenue Growth
- CISS 47.17
- JAGX 19.75
- 52 Week Low
- CISS $0.48
- JAGX $4.40
- 52 Week High
- CISS $13.75
- JAGX $540.00
- Technical
- Relative Strength Index (RSI)
- CISS 16.23
- JAGX 20.41
- Support Level
- CISS $0.68
- JAGX $4.41
- Resistance Level
- CISS $0.74
- JAGX $4.97
- Average True Range (ATR)
- CISS 0.04
- JAGX 0.88
- MACD
- CISS 0.00
- JAGX 0.09
- Stochastic Oscillator
- CISS 9.13
- JAGX 3.35
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.